CB2 Insights (
C.CBII,
OTC:CBTOF,
Forum) launched as a public company in March 2019 and, against trend in the small cap space, operated with cash flows from operations while
growing the company 24 percent year-on-year with Q3 revenues reaching $4.2M.
Recently, oversight bodies such as the FDA began cracking down on medical cannabis providers who claim benefits but have yet to prove safety and efficacy through traditional healthcare channels. The need for real-world evidence is clear and this is where CB2 Insights is set apart from its competitors after five years establishing a strong foundation of technology, data analytical tools and clinical operations.
In this podcast, Stockhouse’s Dave Jackson was joined by the Company’s Chief Executive Officer, Prad Sekar, to discuss CB2’s cutting-edge corporate vision, how it is mainstreaming medical cannabis into traditional healthcare, its cannabis-specific EMR System that’s bringing traditional healthcare protocols to the cannabis industry, and a variety of other industry-related topics.
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.